| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.04 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.079 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.04 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.079 | 0.05 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |